Acquisition Completed
Neurocrine Biosciences acquisition of Soleno Therapeutics
US$2.9bn equity value
Announced 6 Apr 2026 · NASDAQ: SLNO · US$53.00 cash per share
Advisers
Soleno Therapeutics
Target
- Financial adviser
- Legal adviser
- Goodwin

Team: Stuart Cable, Blake Liggio
- Fairness opinion
- Target
- Soleno Therapeutics
- Acquirer
- Neurocrine Biosciences
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 18 May 2026
- Sector
- Biotech
- Tags
- Biotech, Rare Disease, Pharma
In the league tables
- M&A financial advisers, 2026 to date Goldman Sachs #2 · Centerview Partners #5 · Guggenheim Securities #17
- M&A financial advisers, completed, 2026 to date Goldman Sachs #2 · Centerview Partners #7 · Guggenheim Securities #13
- M&A legal advisers, 2026 to date Goodwin #12 · Wilson Sonsini Goodrich & Rosati #22 · Cooley #28
- M&A legal advisers, completed, 2026 to date Goodwin #17 · Cooley #22 · Wilson Sonsini Goodrich & Rosati #29
- Fairness opinion providers, 2026 to date Centerview Partners #4 · Guggenheim Securities #14
Similar deals
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- BioMarin acquisition of Amicus Therapeutics Dec 2025 · US$4.8bn · Biotech
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Quince Therapeutics acquisition of Orphai Therapeutics May 2026 · Biotech
- Servier acquisition of Day One Biopharmaceuticals Mar 2026 · US$2.5bn · Biotech
Sources
- 2026 Centerview Partners: Lead financial advisor to Soleno on its sale to Neurocrine centerviewpartners.com
- Apr 2026 Guggenheim Securities: Financial Advisor to Soleno Therapeutics on its Sale to Neurocrine guggenheimsecurities.com
- 6 Apr 2026 Tender offer communication (SC TO-C), SOLENO THERAPEUTICS INC sec.gov
- 6 Apr 2026 Press release (EX-99.1, exhibit), Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio sec.gov
- 6 Apr 2026 Goodwin Advises Centerview and Guggenheim on $2.9 Billion Sale of Soleno Therapeutics to Neurocrine Biosciences goodwinlaw.com
- 6 Apr 2026 Neurocrine Acquires Soleno for $2.9 Billion cooley.com
- 6 Apr 2026 Press release (PR Newswire), Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio prnewswire.com
- 20 Apr 2026 Tender offer statement (SC TO-T), SOLENO THERAPEUTICS INC sec.gov
- 20 Apr 2026 Target response to tender offer (SC 14D9), SOLENO THERAPEUTICS INC sec.gov
- 18 May 2026 Press release (EX-99.1, exhibit), Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics sec.gov
- 18 May 2026 Press release (PR Newswire), Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics prnewswire.com

